Phase 4
Completed N=89
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
Hypotrichosis
Source: ClinicalTrials.gov NCT00958035 ↗
Enrolled (actual)
89
Serious AEs
2.3%
Results posted
Jan 2012
Primary outcomePrimary: Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4 — 69.6; 48.8 Percentage of Patients
Summary
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified African American/ethnic black subjects exhibiting hypotrichosis of the eyelashes (inadequate or not enough eyelashes).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4 |
69.6; 48.8 | — |
Eligibility Criteria
Inclusion Criteria
- African American/ethnic black
- Adults at least 18 years of age
- Eyelash prominence assessment of minimal or moderate
Exclusion Criteria
- Subjects with uneven lashes or longer on one side than the other
- Any eye disease or abnormality
- Eye surgery
- Severe hyperpigmentation around the eye
- Eyelash implants
- Eyelash extension application
- Any use of eyelash growth products within 6 months
- Any use of prescription eyelash growth products
- Treatments that may affect hair growth
- Requiring eye drop medications for glaucoma
Data sourced from ClinicalTrials.gov (NCT00958035). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.